CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
Matching Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02906579
NCT02906579Phase 2Completed

An Open-label, Phase 2a Trial to Evaluate the Effect of Escalating Doses of IW-1973 on Tolerability, Endothelial Function, and Hemodynamics in Patients With Stable Type 2 Diabetes and Hypertension

Cyclerion Therapeutics·interventional·Posted Sep 20, 2016·Updated Apr 16, 2020

In Brief

A Phase 2 clinical trial evaluating Matching Placebo and IW-1973 for Diabetes Mellitus, Type 2 and Hypertension. Completed, enrolled 11 participants across 1 site.

Detailed Summary

To evaluate the impact of escalating doses of IW-1973 on endothelial function \[using EndoPAT to measure fingertip small vessel pulse volume\], blood pressure (BP), and heart rate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 20, 2016
Enrollment StartSep 1, 2016
Primary CompletionMar 17, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 9.8 years ago

Interventions

Matching Placebodrug

IW-1973drug